• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Astel­las, Pan­th­er­na add or­gan to mR­NA tie-up; Rock­et launch­es sale of six fig­ures worth of stock

3 years ago
R&D
News Briefing

Paul Hud­son and Tri­alSpark's mu­tu­al de­sire to speed up de­vel­op­ment con­verges in three-year, six-drug goal

3 years ago
Deals
Pharma

KalVista ends a PhII study ear­ly af­ter pa­tients suf­fer se­vere and life-threat­en­ing side ef­fects

3 years ago
R&D

Pen­ny stock play­er to re­view all op­tions to try stay­ing afloat af­ter clin­i­cal tri­al fail

3 years ago
R&D

Look­ing to push CAR-T in sol­id tu­mors, Bay Area biotech goes pub­lic in SPAC flip — with slight name change

3 years ago
Financing
Deals

Af­ter 12 months of dig­ging, Pfiz­er opts for one of two Voy­ager cap­sids for gene ther­a­py

3 years ago
Deals
Cell/Gene Tx

Take­da to pull key hy­poparathy­roidism drug from the mar­ket af­ter years of man­u­fac­tur­ing woes

3 years ago
Manufacturing

Tiny Ver­gent seals mod­est Se­ries B in pur­suit of can­cer imag­ing agent

3 years ago
Financing
R&D

In post-Covid life, Vir looks to stomp out in­fluen­za in up to $1B BAR­DA con­tract that boosts GSK-al­lied mAb

3 years ago
Deals
Coronavirus

Bris­tol My­ers inks pro­tein de­grad­er deal via Cel­gene team's link to seed-stage biotech

3 years ago
Startups
Deals

Pfiz­er’s PARP in­hibitor com­bo treat­ment pass­es pri­ma­ry end­point — but de­tails are slim

3 years ago
R&D

Sanofi li­cens­es a pre­clin­i­cal ge­net­ic dis­ease drug from an un­known biotech spun out of the NIH

3 years ago
Deals

Jeff Mar­raz­zo has found a buzzy new biotech cause to cham­pi­on. And once again, he's all in

3 years ago
People
Bioregnum

A year and a half af­ter Cel­lar­i­ty raised $123M, the Flag­ship biotech is back — and it's ready to pick out ...

3 years ago
Financing
Startups

Fa­ther starts lab af­ter in­tel­lec­tu­al prop­er­ty is­sues stymie rare dis­ease drug de­vel­op­ment

3 years ago
People
Pharma

Can a smart­phone app de­tect Covid? Pfiz­er throws down $116M to find out

3 years ago
Deals
Pharma

Big Phar­ma heavy­weights seek tweaks to FDA's clin­i­cal out­come as­sess­ment guid­ance

3 years ago
Pharma
FDA+

An­oth­er warn­ing let­ter for Lupin as FDA iden­ti­fies de­fi­cien­cies at In­dia-based site

3 years ago
FDA+

An­oth­er one bites the dust? FDA warns that emerg­ing Omi­cron sub­vari­ant could make Evusheld ob­so­lete

3 years ago
Coronavirus

In­smed plots up­com­ing med launch­es built on its first drug lessons and con­sumer play­book mar­ket­ing strate­gies

3 years ago
Pharma
Marketing

Roche hires new di­ag­nos­tics chief from with­in, ahead of C-suite shake-up

3 years ago
People
Pharma

FTC chair Lina Khan pledges to use all tools to in­ves­ti­gate PBMs

3 years ago
Pharma

Mesoblast sends in im­proved po­ten­cy as­say, look­ing to re­sub­mit to FDA on acute graft-ver­sus-host dis­ease drug

3 years ago
R&D
FDA+

Star­tup's gold nanocrys­tal ALS drug flops a PhII tri­al, a re­minder of the dis­ease's ob­sta­cles de­spite Amy­lyx OK

3 years ago
R&D
First page Previous page 445446447448449450451 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times